Lisata Therapeutics LSTA 深 沪
等待开盘 10-09 09:30:00 美东时间
1.19
+0.020
+1.71%
华盛通- 最 高1.31
- 今 开1.22
- 成交量 59.04万股
- 最 低 1.13
- 昨 收 1.17
- 总市值 1285.68万
- 52周最高 5.07
- 市盈率 静 --
- 换手率 5.46%
- 52周最低 0.9875
- 委 比 62.60%
- 总股本 1080.41万
- 历史最高 1483.50
- 量 比 16.31
- 振 幅 15.38%
- 历史最低 0.9875
- 每 手 1
- 风险率 1.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
Marea Therapeutics has initiated a Phase 2 clinical trial for MAR002, a potential treatment for acromegaly, after positive Phase 1 results showed effective IGF-1 suppression and dosing as infrequently as every two weeks. Acromegaly, caused by excess growth hormone, leads to severe physical and systemic complications. MAR002, a first-in-class monoclonal antibody targeting the growth hormone receptor, aims to provide meaningful control for patients...
10-05 12:00
Lisata Acquires Marea Therapeutics And Secures $225M Financing To Advance Next-Generation Medicines For Cardioendocrine Diseases
Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002 for the treatment of acromegaly which is advanci...
09-17 21:28
Lisata Therapeutics Announces Suit Against Kuva Labs Seeking Damages And $2M Termination Fee; Cuts Approximately 72% Of Full-Time Employees
Lisata has filed suit in the Delaware Court of Chancery against Kuva over Kuva’s breach of the previously-disclosed Agreement and Plan of Merger dated March 6, 2026 (as amended, the "Merger Agreement"), seeking, among other things, damages for the benefit of its stockholders and the $2,000,000 termi...
08-04 19:14
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
Lisata Therapeutics has filed a lawsuit against Kuva Labs Inc. and its subsidiary over the termination of their merger agreement, seeking damages and a $2 million termination fee. The company is evaluating strategic alternatives to enhance stockholder value, including potential acquisitions, mergers, or asset sales. To reduce expenses, Lisata has implemented a 72% reduction in its workforce, which may impact operations and reputation.
08-04 11:00
Lisata Therapeutics plunges after sale to Kuva Labs terminated
Lisata Therapeutics (LSTA) sank 16% after its planned sale to Kuva Labs was terminated The termination comes after Kuva Labs was unable to obtain sufficient financing to fund its takeover offer, accor...
07-25 00:59
Lisata Therapeutics Ends Kuva Merger, Starts Strategic Review
Lisata Therapeutics ( ($LSTA) ) has shared an announcement. On July 24, 2026, L...
07-25 00:43
Lisata Therapeutics Stock Falls After Hours: Here's Why
Lisata Therapeutics, Inc. (NASDAQ:LSTA) shares slipped in after-hours trading Tuesday after the clinical-stage biotechnology company disclosed an update related to its pending acquisition. Lisata stock closed Tuesday’s regular session down 36.45% at $2.24 before falling 3.57% to $2.16 in after-hours...
07-22 13:03
Lisata Therapeutics Extends Merger Timeline with Kuva Labs
The latest update is out from Lisata Therapeutics ( ($LSTA) ). On July 16, 2026...
07-17 19:29
Kuva Acquisition Commences Tender Offer To Purchase All Issued And Outstanding Shares Of Common Stock Of Lisata Therapeutics For $4.00/Shr In Cash At Closing, Plus One Non-Tradeable Contingent Value Right
Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to achievement of specified milestones The transaction va...
06-10 20:04
